Objectives: The percutaneous endovascular abdominal aortic repair (PEVAR) approach is a minimally invasive technique that has demonstrated clinical benefit over traditional surgical cut down associated with standard endovascular abdominal aortic aneurysm (AAA) repair (EVAR). The objective of our study was to evaluate the budget impact to a Canadian hospital of changing the technique for AAA repair from the EVAR approach to the PEVAR approach. Methods: We examined the budget impact of replacing the EVAR approach with the PEVAR approach in a Canadian hospital that performs 100 endovascular AAA repairs annually. The model incorporates the costs associated with surgery, length of stay, and postoperative complications occurring within 30 days. Results: The use of PEVAR in AAA repair is associated with increased access device costs when compared with the EVAR approach (CAD$1000 vs CAD$400). However, AAA repair completed with the PEVAR approach demonstrates reduced operating time (101 minutes vs 133 minutes), length of stay (2.2 days vs 3.5 days), time in the recovery room (174 minutes vs 193 minutes), and postoperative complications (6% vs 30%), which offset the increased device costs. The model establishes that switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs annually would result in a potential cost avoidance of CAD$245,120. Conclusions: A change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution for Canadian hospitals.
The promise of percutaneous endovascular abdominal aortic repair (PEVAR) and the progressively smaller profiles of devices have served as the basis for an even less invasive, modern-day endovascular abdominal aortic aneurysm (AAA) repair (EVAR) procedure. Evaluated against femoral exposure, a percutaneous approach allows for more frequent use of local anesthesia, a shorter operation, and an earlier ambulation time [1] . Furthermore, by avoiding a groin skin incision, PEVAR supports reduced patient pain, wound complications, and length of stay [1] . The objective of our study was to evaluate the budget impact to a hospital of changing the technique for AAA repair from the EVAR approach to the PEVAR approach.
Methods
We examined the budget impact of replacing the EVAR approach with the PEVAR approach in a Canadian hospital that performs 100 EVARs annually. The model incorporates the costs associated with surgery, length of stay, and postoperative complications occurring within 30 days ( Figure 1 ).
We completed a comprehensive literature review to identify clinical trials comparing clinical outcomes or resource utilisation with PEVAR and EVAR. We performed the literature search in PubMed and Google Scholar in June 2016 and utilised the following search terms: Percutaneous or PEVAR or Endovascular suture or Cutdown or PEVAR vs EVAR AND Abdominal Aortic Repair. A total of 10 retrospective studies and 10 noncomparative prospective studies were identified and excluded due to heterogeneity in methodology. A total of 3 comparative prospective studies were selected for the analysis and their outcomes were pooled [1e3]. The studies included 2 prospective randomized trials [1, 2] and a single nonrandomized prospective trial [3] , representing a total of 239 patients.
The outcomes extracted and included in the budget impact were those that were shown to be statistically significantly different between PEVAR and EVAR in the 3 studies. Significant resource utilisation outcomes included operative time, recovery time, and length of stay. Significant clinical outcomes included groin complications occurring at 30 days, notably bleeding, thrombosis, and lymphocele. In the Nelson et al [1] study, clinical outcomes differed considerably according to the closure device used and therefore only results for patients in the 8F Perclose ProGlide (Abbott Vascular, Markham, ON, Canada) group were included. Other potential clinical benefits from PEVAR, such as reduced complications from local anesthesia, may exist, although they were not captured or significant in these studies and therefore were not incorporated.
The costs were estimated for each procedure (PEVAR and EVAR) and included preoperative care, access and closure devices, the cost of operating room time and other procedure costs, the cost of groin complications, and the cost of recovery and length of stay (Tables 1 and 2). The Ontario Case Costing Initiative is a publically available case-costing database for Ontario hospitals and was used to obtain case cost data for preoperative care, thrombosis requiring endarterectomy, and pharmaceuticals (code 1KA80GQNRN) [4] . A large Canadian Hospital calculated the hourly cost of the operating room (CAD$2300/hour) and the daily cost of an inpatient stay (CAD$1145/day), while the cost of recovery room time was drawn from a pilot study in a Canadian community hospital [8, 9] . The cost of nursing time was based on the average salary of a Canadian nurse [5] . Market research was used to determine the cost of the endovascular aortic stent grafts and medical devices. The costs of local and general anesthesia were sourced from the literature [6, 7] . The costs of bleeding complications were based on the cost of red blood cell transfusion [10] . For the treatment of lymphocele it was assumed that CAD$50 in dressings were applied and 1 hour of nursing time in hospital was required. A multivariate sensitivity analysis was completed using confidence intervals from the literature for clinical outcomes. Cost estimates were varied by AE10%.
There are a number of assumptions in the model. First, the model incorporates postoperative outcomes occurring within 30 days of surgery and may exclude differences between PEVAR and EVAR after that time period. It is also assumed that benefits of PEVAR are identical regardless of the stent graft being used. It is assumed that 3 nurses are needed to assist during surgery and that they receive benefits equal to Model Setup 50% of their salary. It is assumed a weighted average of lab tests and diagnostic tests from Ontario Case Costing Initiative were required for both PEVAR and EVAR. For general anesthesia costs it is assumed the patient was a 75-kg man and that 2 mg/kg was needed for induction and 7.5 mg/kg/h for maintenance. Furthermore, it is assumed that 3 Perclose devices (Abbott Vascular) were utilised per procedure and all procedures are taking place in the operating room. Finally it is assumed that the cost of the device and endovascular repair is independent of the manufacturer. The final budget impact measures the difference in costs associated with surgery, length of stay, and postoperative complications between PEVAR and EVAR ( Figure 1 ).
Results
AAA repair completed with the PEVAR approach from the literature review demonstrates reduced operating time (101 minutes vs 133 minutes), length of stay (2.2 days vs 3.5 days), and time in the recovery room (174 minutes vs 193 minutes) ( Table 1 ). In addition, there is a reduction in postoperative groin complications such as lymphocele, infection, and bleeding (6% vs 30%) ( Table 2 ). From our economic modelling in this article, the use of PEVAR in AAA repair is associated with increased access device costs when compared with the cutdown EVAR approach (CAD$1000 vs CAD$400). These increased device costs are offset by the factors outlined previously. The model establishes that switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs annually would result in a potential cost avoidance of CAD$245,120 ( Figure 2 ).
Discussion
PEVAR was first described in 1999 by Haas et al [12] , who displayed the feasibility of closing vascular access sites with the Prostar XL closure device (Abbott Vascular) using the preclose technique. Benefits attributed to PEVAR included shorter procedure times, reduced need for general anesthesia, lower complication rates, fewer wound complications, and shorter hospital stays [1] .
The first multicentre randomized controlled trial designed to assess the safety and efficacy of PEVAR and to compare percutaneous access with standard open femoral exposure was published recently [1] . Twenty U.S. academic and community institutions and 151 patients were randomized in a 2:1 fashion to PEVAR vs open femoral exposure. The study helped identify the risks and benefits of PEVAR via a preclose technique [1] . Preceding the PEVAR trial, numerous single-centre experiences and nonrandomized trials had been published, but only 1 single-centre randomized trial had been completed [2] .
The conclusion of the PEVAR trial indicated that this technique can be performed safely with >90% technical success and a low incidence of access siteerelated complications [1] . The study demonstrated significantly shorter times to hemostasis (10 minutes vs 23 minutes) and procedural completion (107 minutes vs 141 minutes) using the Perclose ProGlide closure device (Abbott Vascular) in a preclose technique. Additionally, favorable trends were noted with regard to procedural blood loss, groin pain, time to ambulation, and overall quality of life among those undergoing PEVAR. These favorable outcomes were noted despite use of larger French devices (up to 21F), which would possibly have a negative bias on the PEVAR group. Malkawi et al [13] published a systematic review of PEVAR in 2010 to assess primary outcomes including success rate and complications, as well as secondary outcomes such as operative time, hospital stay, time to ambulation, blood loss, and cost. Of the 22 studies reviewed for the time period between 1991-2009, including 1 randomized trial, 10 prospective nonrandomized studies, and 11 retrospective studies, the overall technical success rate was found to be 92% [13] . The PEVAR group had fewer access siteerelated complications (4.4%) and shorter operative times [13] . The most frequent exclusion criteria were scarred groins, femoral artery aneurysms, and heavy femoral artery calcifications [13] . A number of other published studies highlighted that morbid obesity, femoral artery calcification, groin scarring, and large sheath size are regularly associated with percutaneous device malfunction [14] . Meticulous patient selection is of critical importance for successful PEVAR.
One study in this review article reported less cost associated with PEVAR [15] . PEVAR average procedure cost was V99 more than the EVAR group in the randomized study reported in Moore et al [16] . Another study reported an overall increase in procedural cost despite a shorter operative time due to the cost of closure devices (USD$295 per closure device) [17] . Neither study explored the effect of reduced hospital stay on overall cost.
Currently, 1 in 4 patients treated at Targeted Vascular National Surgical Quality Improvement Program centres is getting PEVAR. It is associated with a high success rate, shorter operation time, shorter length of stay, and fewer wound complications compared with cutdown EVAR [18] .
The proportion of EVAR suitable for a percutaneous approach can be as high as 90% [19] . In addition, outpatient EVAR was found to be safe and feasible in a select group of patients undergoing elective procedures [20] .
The cost data used in the model were obtained from peerreviewed literature, the Ontario Case Costing Initiative, and case costing from a large Canadian hospital. Patient outcomes data were obtained from pooling published prospective studies after completing a comprehensive literature review. From our economic modelling in this article, the use of PEVAR in AAA repair is associated with increased access device costs when compared with the cutdown EVAR approach. However, AAA repair completed with the PEVAR approach demonstrates reduced operating time, length of stay, and time in the recovery room. In addition there is a reduction in postoperative complications, which offset the increased device costs. We recognize that some of these published complications are higher than current rates. The rate of transfusion (20% EVAR) is double the current reported rate [20] ; however, it adds very little to the cost overall. Furthermore we did not include the cost of sutures, electrocautery, or operative trays to the open group, which would have increased the cost savings. The model establishes that switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs annually would result in a potential cost avoidance of CAD$245,120.
Of the 3 studies assessed [1e3], 2 mention prior experience with PEVAR before initiating their studies with the largest requiring at least 20 PEVARs performed before becoming an investigator in the study [1] . Two of the 3 studies make no mention of ultrasound guidance for the femoral puncture [2, 3] with 27% used for Prostar placement and 36% for ProGlide placement in the study by Nelson et al [1] . Although experience with PEVAR and use of ultrasound may impact complications and therefore costs, these variables could not be assessed in our model, and there are no studies that have assessed these variables.
In conclusion, from review of the literature PEVAR appears safe and effective in selected patients and may positively influence other aspects of the patient's overall experience. At a time of finite resources, the benefits provided by new interventions must be weighed against their expense. Simulating cost data with clinical datasets allows for the development of modelling tools capable of aiding decision making. A change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution for Canadian hospitals. 
